# Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

Source: https://onco.cc/trials/nct01772420/  
OnCo record `nct01772420` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Eltrombopag and Lenalidomide in Leukaemia, run by Albert Einstein College of Medicine, completed.

## Summary

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia is a phase 2 interventional study registered as NCT01772420 by Albert Einstein College of Medicine, with 52 participants recorded, started 2012-10 and reaching its primary completion in 2020-07-09. Interventions recorded: Eltrombopag Olamine, Laboratory Biomarker Analysis, Lenalidomide. Conditions recorded: Adult Myelodysplastic Syndrome, Anemia, Chronic Myelomonocytic Leukemia.

Linked to the drug Eltrombopag because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01772420
- Phase: 2
- Setting: Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia in Low or Intermediate I Myelodysplastic Syndrome (MDS)
- Sponsor: Albert Einstein College of Medicine
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT01772420: https://clinicaltrials.gov/study/NCT01772420

## Connected records

- cancers: [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/)
- drugs: [Eltrombopag](https://onco.cc/drugs/eltrombopag/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/)

---
JSON: https://onco.cc/api/v1/entities/nct01772420.json